<DOC>
	<DOCNO>NCT00055419</DOCNO>
	<brief_summary>The purpose clinical research study learn safety cetuximab patient stage IV colorectal cancer , may benefit cetuximab .</brief_summary>
	<brief_title>A Study Cetuximab Patients Who Have Stage IV Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects must sign approve informed consent prior study procedure . Subjects histologically pathologically confirm metastatic colorectal cancer , EGFRpositive IHC ( may base archival sample ) Subjects ECOG performance status 0 , 1 2 . Subjects fail , either due lack efficacy due intolerance , available chemotherapy treatment metastatic colorectal cancer . Subjects fail meet eligibility criterion exist cetuximab trial . Subjects must receive least two chemotherapy regimens metastatic disease OR adjuvant therapy plus one chemotherapy regimen metastatic disease , provide subject progress within 6 month complete adjuvant therapy . Prior chemotherapy must include follow drug : irinotecan , oxaliplatin , fluoropyrimidine . Subjects adequately recovered recent surgery , radiation therapy chemotherapy . Subjects accessible treatment followup . Subjects enrol trial must treat participate center . Subjects great equal 18 year age . Women childbearing potential must use adequate method contraception avoid pregnancy throughout study 4 week afterwards . Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 4 week study . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Sexually active , fertile men use adequate birth control . Subjects dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent . Subjects serious uncontrolled medical disorder would impair ability patient receive protocol therapy . Subjects history uncontrolled angina , arrhythmia , congestive heart failure , myocardial infarction within previous 6 month . Subjects concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . Subjects previous malignancy without evidence disease &gt; 5 year allow enter trial . Subjects history severe hypersensitivity reaction and/or anaphylaxis result administration protein base therapeutic agent . Subjects inadequate hematologic function define absolute neutrophil count ( ANC ) &lt; 1,250/mm3 , platelet count &lt; 75,000/mm3 , hemoglobin level &lt; 8 g/dL . Subjects inadequate hepatic function , define total bilirubin level Â³3 time upper limit normal ( ULN ) aspartate transaminase ( AST ) alanine transaminase ( ALT ) level &gt; 5 x ULN . Subjects inadequate renal function define serum creatinine level &gt; 2.5 x ULN . Prior cetuximab therapy , prior randomization study include cetuximab therapy treatment arm , prior therapy target EGFR pathway . A history prior therapy chimerized murine monoclonal antibody . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study . A history cetuximab therapy target EGFR receptor . A history prior anticancer murine monoclonal antibody therapy . Additional concurrent chemotherapy investigational anticancer agent may administer subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Stage IV colorectal cancer</keyword>
</DOC>